ClinicalTrials.gg
RecruitingNCT06654401Updated Dec 20, 2024

Electrical Cardioversion As a Predictor in Postoperative Preservation of Sinus Rhythm

An interventional study of Transthoracic echocardiography and 24-hour ECG Monitor in Atrial Fibrillation and Atrial Fibrillation, Persistent, sponsored by Saint Petersburg State University, Russia. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Saint Petersburg State University, Russia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Atrial Fibrillation with a site in Russian Federation — 4 open to participants now, 5 under way, none of them phase 3. Atrial Fibrillation · Russian Federation.

Planned enrollment
49th of 80
125 · median 175
Started
2024
the only one that year
No phase
18 of 107
3 open now
Registered
106th of 107
by date

Among the 107 studies in Atrial Fibrillation with a site in Russian Federation, this one is the 49th largest by planned enrollment of the 80 interventional ones that give a count, is the only one that started in 2024, is one of 18 with no phase, and was the 106th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 107 studies in Atrial Fibrillation with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Atrial Fibrillation with a site in Russian Federation, or all of them as a file.
02

Study summary

The aim of this study is to evaluate benefits of electric cardioversion in the early and long-term postoperative period in patients after radiofrequency catheter isolation of pulmonary veins. Parameters of the left atrium will be evaluated by transthoracic echocardiography and electroanatomic mapping. Preservation of the sinus rhythm will be assessed by 24-hour electrocardiographic monitoring.

The main question that is planned to be answered is:

Does a reverse remodeling of the left atrium and/or a decrease in the progression of the fibrosis zone occur after performing electrical cardioversion (and before subsequent catheter ablation) in patients with persistent and long-standing persistent atrial fibrillation (AF)? Can performed electrical cardioversion serve as a predictor of AF freedom in this group of patients?

Participants will undergo a follow-up examinations (echocardiography, ECG, 24-hour ECG monitoring) at the 3rd, 6th and 12th months after catheter ablation. Based on the results of these examinations, the recurrence rate of AF will be estimated.

Two groups of patients will include both persistent and long-standing persistent AF. Experimental group will include patients who underwent electrical cardioversion before the intervention, and active comparator group will include those patients who did not undergo it. The experimental group will be subdivided into a persistent AF patients who were successfully cardioverted in sinus rhythm and persistent AF patients who failed to restore sinus rhythm during DC at the time of catheter ablation. Analysis and comparison of subgroups will be performed.

03

Conditions studied

  • Atrial Fibrillation
  • Atrial Fibrillation, Persistent

Browse trials for

Keywords

  • Atrial Fibrillation
  • Cardioversion
  • Catheter ablation
  • Late recurrence
  • Left atrial voltage
  • Left atrial volume
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed by the patient to participate in the study.
  • Persistent atrial fibrillation resistant to antiarrhythmic drugs for 6 months or more
  • The size of the left atrium is less than 55 mm, volume is less than 130 ml, volume index (LP) is less than 55 ml/m2

Exclusion criteria

Exclusion Criteria:

  • Reversible causes of atrial fibrillation (hyperthyroidism, pericarditis, myocarditis).
  • Patients in need of myocardial revascularization and/or heart valvular disease correction.
  • Any previous intervention (including MAZE surgery, thoracoscopic ablation; implanted occluder of the auricle of the left atrium.).
  • Patients with severe concomitant pathology requiring correction.
  • for administration of anticoagulant therapy.
  • Documented presence of a blood clot in the cavity of the left atrium or other reasons preventing the insertion of catheters into the left atrium.
  • of 40 or more
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
125 participants (estimated)

Study arms

  • Experimental
    Radiofrequency pulmonary vein isolation in patients with previous electrical cardioversion

    Depending on the duration of atrial fibrillation and anatomic parameters of the left atrium (according to heart ultrasound), patients will undergo electric cardioversion before the primary radiofrequency catether pulmonary veins' isolation. The experimental group will be subdivided into a persistent AF patients who were successfully cardioverted in sinus rhythm and persistent AF patients who failed to restore sinus rhythm during DC at the time of catheter ablation.

    Diagnostic Test: Transthoracic echocardiography · Diagnostic Test: 24-hour ECG Monitor · Procedure: Electroanatomic mapping

  • Active comparator
    Radiofrequency pulmonary vein isolation in patients without previous electrical cardioversion

    Primary interventional treatment is performed without restoration of the sinus rhythm.

    Diagnostic Test: Transthoracic echocardiography · Diagnostic Test: 24-hour ECG Monitor · Procedure: Electroanatomic mapping

Interventions

  • Diagnostic testTransthoracic echocardiography

    Standard assessment of the parameters of the left atrium: size, volume, volume indices

  • Diagnostic test24-hour ECG Monitor

    Assessment of cardiac arrhythmias according to 24-hour monitoring data

  • ProcedureElectroanatomic mapping

    Intraoperative assessment of low voltage areas (potential fibrosis zones)

06

What researchers measure

Primary outcomes

  1. Freedom from atrial fibrillation 6 months after catheter ablation

    Absence of events of sustained atrial tachycardia according to 24-hour ECG monitoring

    Time frame: Echocardiographic assessment of the parameters of the left atrium and 24-hour ECG monitoring is performed at the time of admission to the hospital; after 3,6 and 12 months after intervention or the latest data in the event of death, whenever comes first

Secondary outcomes

  1. Reverse remodeling of the left atrium and improvement of the contractility of the left ventricle

    An increase in the LV ejection fraction, a decrease in the volume and size of the left atrium according to transthoracic echocardiography

    Time frame: Echocardiographic assessment of the parameters of the left atrium and 24-hour ECG monitoring is performed at the time of admission to the hospital; after 3,6 and 12 months after intervention or the latest data in the event of death, whenever comes first

  2. Freedom from atrial fibrillation 12 months after catheter ablation

    Absence of events of sustained atrial tachycardia according to 24-hour monitoring

    Time frame: Echocardiographic assessment of the parameters of the left atrium and 24-hour ECG monitoring is performed at the time of admission to the hospital; after 3,6 and 12 months after intervention or the latest data in the event of death, whenever comes first

  3. Improving the quality of life of patients with atrial fibrillation

    Assessment of the quality of life of patients with atrial fibrillation based on a questionnaire: Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Questionnaire - provides an overall score; plus scores for symptoms, daily activities, treatment concerns, and treatment satisfaction. Overall or subscale scores range from 0-100. A score of 0 corresponds to complete disability (or responding "extremely" limited, difficult or bothersome to all questions answered), while a score of 100 corresponds to no disability (or responding "not at all" limited, difficult or bothersome to all questions answered).

    Time frame: Patients fill out questionnaires upon admission to the hospital; 3, 6 and 12 months after surgical treatment or the latest data in the event of death, whenever comes first

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kamada H, Mori K, Ueda N, Wakamiya A, Nakajima K, Kamakura T, Wada M, Ishibashi K, Yamagata K, Inoue Y, Miyamoto K, Nagase S, Noda T, Izumi C, Noguchi T, Kusano K, Aiba T. Impact of Pre-Ablation Direct Current Cardioversion for Persistent Atrial Fibrillation to Predict Recurrence of Atrial Fibrillation after Catheter Ablation. Int Heart J. 2022;63(5):828-836. doi: 10.1536/ihj.22-135. PubMed 36184544 ↗
  • Kang JH, Lee DI, Kim S, Kim MN, Park YM, Ban JE, Choi JI, Lim HE, Park SW, Kim YH. Prediction of long-term outcomes of catheter ablation of persistent atrial fibrillation by parameters of preablation DC cardioversion. J Cardiovasc Electrophysiol. 2012 Nov;23(11):1165-70. doi: 10.1111/j.1540-8167.2012.02339.x. Epub 2012 Aug 8. PubMed 22882453 ↗
  • Choi SH, Yu HT, Kim D, Park JW, Kim TH, Uhm JS, Joung B, Lee MH, Hwang C, Pak HN. Late recurrence of atrial fibrillation 5 years after catheter ablation: predictors and outcome. Europace. 2023 May 19;25(5):euad113. doi: 10.1093/europace/euad113. PubMed 37099677 ↗
  • Hanaki Y, Machino-Ohtsuka T, Aonuma K, Komatsu Y, Machino T, Yamasaki H, Igarashi M, Sekiguchi Y, Nogami A, Ieda M. Preprocedural restoration of sinus rhythm and left atrial strain predict outcomes of catheter ablation for long-standing persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2020 Jul;31(7):1709-1718. doi: 10.1111/jce.14540. Epub 2020 May 16. PubMed 32391641 ↗
  • Lizewska-Springer A, Dabrowska-Kugacka A, Lewicka E, Drelich L, Krolak T, Raczak G. Echocardiographic predictors of atrial fibrillation recurrence after catheter ablation: A literature review. Cardiol J. 2020;27(6):848-856. doi: 10.5603/CJ.a2018.0067. Epub 2018 Jun 20. PubMed 29924375 ↗

Individual participant data

Plan to share: No — Individual participant data is not planned to be shared with other parties

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Sep 2025, 10 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 10 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 23, 2024
StartActual
Nov 1, 2024
Primary completionEst.
Sep 1, 2025
CompletionEst.
Jan 1, 2026
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06654401
Lead sponsor
Saint Petersburg State University, Russia
Responsible party
Shmatov Dmitry (Deputy Director (Cardiac Surgery), Saint Petersburg State University, Russia) — Principal investigator
First posted
Oct 23, 2024
Start date
Nov 1, 2024
Primary completion
Sep 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Dec 20, 2024

Study contacts

Anton A Sheremet, MD
Contact
sheremet.dr@yandex.ru
+79313084398
Aleksei A Filippov, MD, PhD
Contact
aleksei.filippov.chb@gmail.com
+79819553639

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion